All studies
CompletedPhase IIIInterventional

NicotinAMide in Glaucoma (NAMinG): a randomised, placebo-controlled, multi-centre, Phase III trial

Glaucoma is a common eye condition that can cause gradual sight loss by damaging the nerve at the back of the eye (the optic nerve). Current treatments lower pressure inside the eye, but some people still lose vision. Researchers want to find new ways to keep eye nerves healthy and working well. This trial is testing whether nicotinamide, a form of vitamin B3 taken as a daily tablet, can protect nerve cells in the eye from damage. The study is open to adults diagnosed with early to moderate open-angle glaucoma within the last 12 months. All participants will keep having their normal NHS treatment, such as eye drops or laser care. Half of the volunteers will receive nicotinamide tablets, and half will receive a dummy tablet (placebo). The trial lasts 30 months and involves eight clinic visits, including standard eye tests and simple blood checks.

At a glance

Status
Completed
Phase
Phase III
Sponsor
UCL Comprehensive Clinical Trials Unit
Enrolment target
376
Start
18 Jan 2024
Estimated completion
30 Apr 2026

What is this study about?

Glaucoma is one of the leading causes of sight loss in the UK. It happens when the optic nerve, which connects the eye to the brain, becomes damaged. In many cases, this damage is linked to raised pressure inside the eye. Current NHS treatments, such as daily eye drops or gentle laser therapy, aim to lower this pressure. While these treatments help many people, some patients continue to lose vision over time.

Scientists believe that nerve cells in the eye need a huge amount of energy to stay alive and resist damage. Inside each cell are tiny power stations called mitochondria. In people with glaucoma, these power stations may struggle to produce enough energy. Nicotinamide, a form of vitamin B3, is thought to boost the way these cell batteries work, helping the eye nerves stay strong and healthy.

This study, called the NAMinG trial, aims to see if taking a daily vitamin B3 pill can stop or slow down vision loss when added to normal eye care. If the trial is successful, it could offer a simple, safe, and low-cost tablet to help protect the sight of thousands of people living with glaucoma.

Key takeaways

  • Tests whether vitamin B3 (nicotinamide) tablets can protect vision in open-angle glaucoma.
  • For adults diagnosed with early to moderate glaucoma in the last 12 months.
  • You continue all your normal NHS glaucoma treatments throughout the study.
  • Involves eight clinic visits over two and a half years, with travel expenses reimbursed up to £30 per extra visit.
  • Half of the volunteers take vitamin B3 and half take a dummy pill (placebo).

Who may be eligible?

You may be able to join this study if you are 18 or older and were diagnosed with early to moderate open-angle glaucoma in at least one eye within the past 12 months. You will also need to have good enough vision to complete standard eye clinic tests and be willing to attend clinic visits over two and a half years.

You will not be able to take part if you are pregnant, planning a pregnancy, or breastfeeding, because the safety of the study pill during pregnancy is not yet known. Both men and women taking part must agree to use reliable contraception during the trial.

People with certain other medical conditions cannot join. These include serious liver or kidney problems, recent cancer, or other eye conditions that affect vision, such as significant cataracts or diabetic eye disease. You also cannot take part if you take certain medicines, including specific treatments for seizures or tuberculosis.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I was diagnosed with open-angle glaucoma within the last 12 months.
  3. I still have reasonable vision in at least one eye.
  4. I am not pregnant, breastfeeding, or planning a pregnancy.
  5. I do not have severe kidney problems or liver disease.
  6. I am willing to attend eight hospital appointments over 30 months.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for 30 months (two and a half years). During this time, you will visit the eye clinic eight times. For most people, this is only three more visits than usual NHS care. Where possible, your research appointments will be arranged on the same day as your routine check-ups.

At your visits, you will have standard eye checks, including visual field tests where you click a button when you see flashes of light. You will also have simple blood tests and answer short questions about your daily health. You will be given daily tablets to take at home. A computer will randomly decide whether you get the vitamin B3 tablets or dummy tablets (placebo). Neither you nor your doctor can choose which pill you receive.

You will continue using your regular glaucoma drops or other treatments throughout the trial. You will also keep a simple diary to note when you take your pills and record any symptoms. Travel costs of up to £30 per extra visit will be paid to help with your journey.

Potential risks and benefits

Taking part may not help your vision directly, but the results could help improve glaucoma care for everyone in the future. Nicotinamide is generally very safe and well-tolerated. However, like any medicine, it can cause mild side effects in some people, such as skin flushing, an upset stomach, mild headaches, or tiredness. Routine blood tests can sometimes cause a small bruise or brief discomfort. Your health will be closely watched at every visit, and you will be given an emergency contact card to carry. You are free to leave the trial at any time without giving a reason, and your normal NHS eye care will never be affected.

Locations (10)

  • Moorfields Eye Hospital
    Approximate
    London, England
  • Kings College Hospital
    Approximate
    London, England
  • Queen Alexandra Hospital
    Approximate
    Portsmouth, England
  • Queen Victoria Hospital Cdc
    City only
    East Grinstead, England
  • Barnet Hospital
    Approximate
    Barnet, England
  • Addenbrookes
    Unverified
    Cambridge, England
  • Queens Medical Centre, Nottingham University Hospital
    Unverified
    Nottingham, England
  • Royal Liverpool University Hospital NHS Trust
    Unverified
    Liverpool, England
  • Belfast City Hospital
    Unverified
    Belfast, Northern Ireland
  • Manchester Royal Eye Hospital
    Unverified
    Manchester, England

Common questions

Will I have to stop using my normal glaucoma eye drops?

No. You will carry on with all your regular NHS eye treatments, including drops or laser therapy, just as you normally do.

What is a placebo?

A placebo is a dummy pill that looks exactly like the study medicine but contains no active ingredient. It helps researchers fairly compare whether the real vitamin B3 makes a genuine difference.

Can I choose to take the vitamin B3 instead of the placebo?

No. A computer assigns participants by chance to ensure the study is fair and unbiased. Neither you nor your eye doctor will know which tablet you are taking until the study ends.

What should I do if I feel unwell while taking the tablets?

You should note any symptoms in your study diary and contact the research team using the phone number on your trial alert card. They are always available to advise you.

Will taking part cost me anything?

No. The study tablets and all extra tests are completely free. You can also claim up to £30 per extra hospital visit to help cover your travel costs.

How to find out more

Felicia Ikeji

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.